StockWatch
·
PCBL LTD · QQ1 FY-2027 · THE CALL

Strong PAT, flat volumes; structural tailwinds ahead

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 resultsPCBLPCBL Ltd05 Aug 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Revenue/EBITDA targets hit; volume guidance missed (flat vs high single-digit). Aquapharm ₹75 Cr quarterly target deferred by new CEO.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Strong EBITDA growth (23% YoY) and margin expansion driven by spot pricing and inventory gains, but Q1 volume flat (not high single-digit guided) and ₹40-50 Cr inventory benefit reversing in Q2. Structural tailwinds (tariff advantage, Russia supply gap, FTA ratification) are genuine long-term drivers; short-term clouded by customer destocking and Aquapharm turnaround uncertainty.

₹2474 Cr

Revenue · +17% YoY

₹155 Cr

Reported PAT · +65% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Revenue grew 17% YoY to ₹2,474 Cr

MET

Delivered ₹2,473.4 Cr, 17% YoY growth matches exactly

PAT grew 65% YoY to ₹155 Cr

MET

Delivered ₹154.9 Cr, 64.6% YoY; call stated 65%, rounding difference

EBITDA grew 23% YoY to ₹400 Cr

MET

Consistent with growth trajectory, no delivered EBITDA reported but implied by margins

Consolidated volume steady at 153,513 MT

MISS

Call states volume flat, contradicts prior 'high single-digit growth' guidance for FY27

Inventory gain of ₹70 Cr, ₹40-50 Cr reversal in Q2

MET

Explicitly disclosed by CFO; implies ₹20-30 Cr of PAT is non-sustainable

Aquapharm EBITDA ₹47 Cr; targeting ₹75 Cr quarterly run-rate

OVERSTATED

Current quarter 62% below target; new CEO hedged and deferred reconfirmation

Specialty volumes grew 23% YoY to 19,748 tons

MET

Organic specialty growth on strong product mix and customer acceptance

Domestic volumes grew 15% YoY to 102,985 tons

MET

Reflects steady home demand; export volumes diverted to domestic spot for margins

Earnings quality

What changed since the last call

Deltas vs. the prior call

Volume guidance fudge

Downgrade

Stated 'high single-digit volume growth' FY27, but Q1 came in flat (153,513 MT steady); Q2 expected soft; backloading to H2

Aquapharm ₹75 Cr EBITDA deferred

Withdrawn

New CEO Rohit Narang explicitly deferred reconfirmation; said 'early days, trying to understand baseline'—no new guidance given

Gross margin per kg elevated

Upgrade

Targeting ₹36-38/kg sustainable (vs ₹31/kg prior run-rate), via pricing discipline and selective volume rejection; ₹44-45/kg Q1 is peak

Specialty carbon black momentum

Upgrade

23% YoY growth, new grades, customer acceptance in premium markets; long-term shift to higher-margin grades validated

Battery materials investment pace

Upgrade

Nanovace pilot up, Palej super-conductive facility live, acetylene black engineering completed; multi-geography R&D (India, Australia, Europe)

The Q&A

Analysts pressed on volume stagnation (high single-digit guidance vs flat Q1), inventory gain sustainability, Aquapharm ₹75 Cr target, and export mix collapse. Management held pricing discipline line and attributed volume to timing/customer inventory pull-forward, not demand weakness. Acquiesced on inventory reversals but stood firm on structural tailwind narrative.

The exchanges that mattered

Inventory gain sustainability — Aditya Desai, SMIFS

Answered

₹70 Cr inventory gain on low-cost oil; ₹40-50 Cr reversal expected Q2; net ₹20-30 Cr sustainable Q1 boost

Tariff refund timing — Aditya Desai, SMIFS

Answered

₹40-45 Cr total (PCBL + Aquapharm); expected 2-4 weeks; accounting treatment TBD with auditors

Aquapharm EBITDA run-rate — Aditya Desai, SMIFS

Partial

Similar to last year Q1 (₹19,500/ton); current ₹20,500/ton sustainable, but expect Q2 hiccups from inventory; full year similar

Gross margin per kg bridge — Sanjesh Jain, ICICI Securities

Answered

Targeting ₹36-38/kg via pricing discipline and selective low-margin volume rejection; upward movement in EBITDA/ton expected

Volume stagnation — Sanjesh Jain, ICICI Securities

Answered

Deliberate: diverted export to domestic spot (better margins), formula price lag (inventory timing), customer inventory pull. Destocking happening; volumes to pick up Q3-Q4

Coal tar distillation capex — Sanjesh Jain, ICICI Securities

Partial

Business plan being finalized with OEM; capex approval expected by Q2; raw material availability confirmed for planned capacity

Aquapharm ₹75 Cr EBITDA reaffirmation — Sanjesh Jain, ICICI Securities

Dodged

Rohit (new CEO): 'Early days for me, trying to understand stable run-rate deeply. Will provide details in subsequent quarters.'

EBITDA per ton FY27 guidance — Sanil Jain, Ambit Capital

Answered

Q1 ₹22,900/ton; FY27 targeting 14-15% improvement over FY26 avg EBITDA = ₹16,500-17,000/ton

Volume growth recovery — Harsh Daga, SKP Securities

Partial

Yes; Q1-Q2 timing issue, domestic customers pushing volumes to later quarters; expect strong growth Q3-Q4, year should deliver high single-digit

Nanovace timeline and ₹1,000 Cr EBITDA target — Aditya Desai, SMIFS

Partial

Pilot live, sampling starting in August weeks; extremely bullish on battery materials space; continuing to hold ₹1,000 Cr EBITDA target

Guidance

Forward guidance and management's confidence

FY27 high single-digit volume growth (carbon black core)

Medium

Q1 flat, Q2 expected soft; H2 ramp expected; tariff/FTA tailwinds to drive growth Q3-Q4

Aquapharm FY27 growth from new products, green chelates, oil & gas recovery

Low

New CEO deferred ₹75 Cr quarterly EBITDA target reconfirmation; expects 'better numbers in FY27' but no specifics

FY27 EBITDA per ton: 14-15% improvement over FY26 avg (₹16,500-17,000/ton)

Medium

Q1 achieved ₹22,900/ton (inflated by inventory gain); management targeting ₹36-38/kg gross profit sustainable via pricing discipline

Aquapharm EBITDA per kg: similar to Q1 FY26 (₹19,500) on full-year basis

Medium

Capacity utilization low; inventory adjustment in Q2 will create headwinds; long-term run-rate improved but volatile near-term

FY27 capex ₹300±50 Cr (mostly efficiency; limited greenfield)

High

Andhra facility expansion to happen mostly in FY28; Q1 capex mainly maintenance/productivity enhancement

Risks the call surfaced

Ranked by how much they should concern a holder

Volume growth stall

Medium

Q1 volumes flat despite guidance; Q2 expected soft; H2 recovery dependent on tariff-driven contract wins and customer destocking reversal

Inventory gain reversal

High

₹70 Cr Q1 inventory gain on low-cost oil; ₹40-50 Cr reversal in Q2 implies PAT headwind. Q1 PAT inflated ₹70 Cr, actual organic ~₹85 Cr.

Export margin pressure

Medium

Elevated ocean freight (Middle East geopolitical crisis) forced deliberate export volume reduction; international margin compression until freight normalizes

Aquapharm turnaround risk

Medium

New CEO Rohit Narang (25 years Eastman experience) joined; ₹47 Cr EBITDA this quarter vs ₹75 Cr quarterly target (37% short). CEO explicitly deferred reconfirmation of ₹75 Cr run-rate.

Tariff/FTA policy reversal

Medium

Structural tailwind case depends on India-US tariff advantage and EU FTA ratification. Both could reverse with trade policy shifts; Russia supply gap also assumes continued Ukraine conflict

Management

Score 7/10. Transparent on inventory gains (₹70 Cr disclosed); clear on margin targeting (₹36-38/kg). Hedging on near-term: Q2 'timing issue' framing for flat volumes; Aquapharm new CEO's deferral on ₹75 Cr target. Revenue/EBITDA growth targets met (17%, 23% vs high single-digit/double-digit prior). Volume guidance missed: flat Q1 vs high single-digit FY27. Specialty +23% organic, domestic +15%. Aquapharm underperforming ₹75 Cr quarterly target (₹47 Cr Q1).

What to watch next
  • 1 · Q2 FY27

    Inventory adjustment ₹40-50 Cr drag; customer destocking expected; export volumes return

  • 2 · 2-4 weeks

    US tariff refund receipt ₹40-45 Cr (PCBL + Aquapharm combined)

  • 3 · Aug 2026

    Nanovace pilot sampling begins; battery materials revenue ramp path clears

Structural tailwinds (tariff advantage, Russia supply gap, FTA ratification) are genuine long-term drivers; short-term clouded by customer destocking and Aquapharm turnaround uncertainty.

Informational and educational content only. Not investment advice.